{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T12:15:53Z","timestamp":1793103353057,"version":"4.5.0"},"reference-count":48,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T00:00:00Z","timestamp":1586908800000},"content-version":"unspecified","delay-in-days":14,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["KL2TR001077"],"award-info":[{"award-number":["KL2TR001077"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Taichung Veterans General Hospital and Veterans Affairs Council, R.O.C."},{"DOI":"10.13039\/100007028","name":"the Helmsley Charitable Trust","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007028","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Michael E. DeBakey VA Medical Center","award":["CIN 13-413"],"award-info":[{"award-number":["CIN 13-413"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Gastroenterol"],"accepted":{"date-parts":[[2019,12,6]]},"published-print":{"date-parts":[[2020,4]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>Elevated tumour necrosis factor (TNF)-\u03b1 has been implicated in the progression of liver fibrosis and pathogenesis of non-alcoholic fatty liver disease (NAFLD). We aim to investigate the impact of anti-TNF-\u03b1 agents on the development of cirrhosis and NAFLD.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>This retrospective cohort study used a US claims database between 1 January 2010 and 31 December 2016. We identified adult patients with ankylosing spondylitis, inflammatory bowel disease, psoriatic arthritis or rheumatoid arthritis. Anti-TNF-\u03b1 agents of interest included adalimumab, certolizumab, etanercept, golimumab and infliximab. The primary composite outcome was the development of new-onset cirrhosis, NAFLD or non-alcoholic steatohepatitis (NASH). The secondary outcomes were the development of (1) cirrhosis and (2) NAFLD or NASH. Propensity score for anti-TNF-\u03b1 agent use was generated by logistic regression. Cox proportional hazard models adjusting for the propensity score were used with regard to time-varying anti-TNF-\u03b1 agent exposure.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>This study included 226\u2009555 incident patients with immune-related diseases. During the median 1.5 years follow-up, there was an increased hazard with anti-TNF-\u03b1 agent use in regard to liver outcomes (composite outcome HR: 1.47, 95%\u2009CI 1.27 to 1.70; cirrhosis HR 1.47, 95%\u2009CI 0.96 to 2.23; NAFLD or NASH HR 1.53, 95%\u2009CI 1.32 to 1.77). The composite outcome hazard was increased for each immune-related disease (HR 1.25\u20131.90).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>In the short term, we did not observe a beneficial effect of anti-TNF-\u03b1 agent use for development of cirrhosis, NAFLD or NASH in patients with immune-related diseases.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjgast-2019-000349","type":"journal-article","created":{"date-parts":[[2020,4,16]],"date-time":"2020-04-16T06:45:15Z","timestamp":1587019515000},"page":"e000349","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":32,"title":["Antitumour necrosis factor-\u03b1 agents and development of new-onset cirrhosis or non-alcoholic fatty liver disease: a retrospective cohort"],"prefix":"10.1136","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5468-1329","authenticated-orcid":false,"given":"Kuo-Tung","family":"Tang","sequence":"first","affiliation":[{"name":"Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital, Taichung, Taiwan"},{"name":"Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA"},{"name":"School of Medicine, National Yang-Ming University, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois","family":"Dufour","sequence":"additional","affiliation":[{"name":"Department of Visceral Surgery and Medicine, Inselspital University Hospital Bern, Bern, Switzerland"},{"name":"Department of Biomedical Research, University of Bern, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Hung","family":"Chen","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology & Hepatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben","family":"Hernaez","sequence":"additional","affiliation":[{"name":"Section of Gastroenterology, Michael E DeBakey VA Medical Center, Houston, Texas, USA"},{"name":"Center for Innovations in Quality, Effectiveness and Safety, Michael E DeBakey VA Medical Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6311-2611","authenticated-orcid":false,"given":"Susan","family":"Hutfless","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology & Hepatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,4,15]]},"reference":[{"key":"2025073012483083000_7.1.e000349.1","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2017.187"},{"key":"2025073012483083000_7.1.e000349.2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210715"},{"key":"2025073012483083000_7.1.e000349.3","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208337"},{"key":"2025073012483083000_7.1.e000349.4","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjw169"},{"key":"2025073012483083000_7.1.e000349.5","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1093\/ecco-jcc\/jjx009","article-title":"Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management","volume":"11","author":"Harbord","year":"2017","journal-title":"J Crohns Colitis"},{"key":"2025073012483083000_7.1.e000349.6","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.091926"},{"key":"2025073012483083000_7.1.e000349.7","doi-asserted-by":"publisher","DOI":"10.1186\/ar3874"},{"key":"2025073012483083000_7.1.e000349.8","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2011.168"},{"key":"2025073012483083000_7.1.e000349.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.09.014"},{"key":"2025073012483083000_7.1.e000349.10","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s10238-015-0347-4","article-title":"Severity of non-alcoholic fatty liver disease is associated with high systemic levels of tumor necrosis factor alpha and low serum interleukin 10 in morbidly obese patients","volume":"16","author":"Paredes-Turrubiarte","year":"2016","journal-title":"Clin Exp Med"},{"key":"2025073012483083000_7.1.e000349.11","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1055\/s-0043-118666","article-title":"Pivotal role of TNF-\u03b1 in the development and progression of nonalcoholic fatty liver disease in a murine model","volume":"50","author":"Kakino","year":"2018","journal-title":"Horm Metab Res"},{"key":"2025073012483083000_7.1.e000349.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.07.033"},{"key":"2025073012483083000_7.1.e000349.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200011163432007"},{"key":"2025073012483083000_7.1.e000349.14","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510260621"},{"key":"2025073012483083000_7.1.e000349.15","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(99)70354-9"},{"key":"2025073012483083000_7.1.e000349.16","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2005.071118"},{"key":"2025073012483083000_7.1.e000349.17","doi-asserted-by":"publisher","DOI":"10.1007\/s10753-007-9053-z"},{"key":"2025073012483083000_7.1.e000349.18","doi-asserted-by":"publisher","DOI":"10.1677\/JOE-07-0234"},{"key":"2025073012483083000_7.1.e000349.19","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24544"},{"key":"2025073012483083000_7.1.e000349.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2004.11.025"},{"key":"2025073012483083000_7.1.e000349.21","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(02)00442-7"},{"key":"2025073012483083000_7.1.e000349.22","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(02)00230-1"},{"key":"2025073012483083000_7.1.e000349.23","doi-asserted-by":"publisher","DOI":"10.1210\/er.2006-0031"},{"key":"2025073012483083000_7.1.e000349.24","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13578-016-0074-x","article-title":"The protective or damaging effect of tumor necrosis factor-\u03b1 in acute liver injury is concentration-dependent","volume":"6","author":"Dong","year":"2016","journal-title":"Cell Biosci"},{"key":"2025073012483083000_7.1.e000349.25","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s00296-015-3369-z","article-title":"Liver cirrhosis in selected autoimmune diseases: a nationwide cohort study in Taiwan","volume":"36","author":"Tung","year":"2016","journal-title":"Rheumatol Int"},{"key":"2025073012483083000_7.1.e000349.26","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2002.001826"},{"key":"2025073012483083000_7.1.e000349.27","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-10-20"},{"key":"2025073012483083000_7.1.e000349.28","doi-asserted-by":"publisher","DOI":"10.1198\/000313001750358491"},{"key":"2025073012483083000_7.1.e000349.29","doi-asserted-by":"crossref","unstructured":"Smith AR , Goodrich NP , Beil CA , et al . Graphical representation of survival curves in the presence of time-dependent categorical covariates with application to liver transplantation. Journal of Applied Statistics 2018:1\u201312.","DOI":"10.1080\/02664763.2018.1558187"},{"key":"2025073012483083000_7.1.e000349.30","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20206"},{"key":"2025073012483083000_7.1.e000349.31","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206711"},{"key":"2025073012483083000_7.1.e000349.32","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i10.2515"},{"key":"2025073012483083000_7.1.e000349.33","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.111391"},{"key":"2025073012483083000_7.1.e000349.34","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.116194"},{"key":"2025073012483083000_7.1.e000349.35","doi-asserted-by":"publisher","DOI":"10.1002\/art.23721"},{"key":"2025073012483083000_7.1.e000349.36","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19082199","article-title":"Harmful Effects and Potential Benefits of Anti-Tumor Necrosis Factor (TNF)-\u03b1 on the Liver","volume":"19","author":"Lopetuso","year":"2018","journal-title":"Int J Mol Sci"},{"key":"2025073012483083000_7.1.e000349.37","first-page":"463","article-title":"High prevalence of non-alcoholic fatty liver disease in patients with inflammatory bowel disease receiving anti-tumor necrosis factor therapy","volume":"32","author":"Likhitsup","year":"2019","journal-title":"Ann Gastroenterol"},{"key":"2025073012483083000_7.1.e000349.38","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1097\/MEG.0000000000001144","article-title":"Effects of inflammatory bowel disease treatment on the risk of nonalcoholic fatty liver disease: a meta-analysis","volume":"30","author":"Lapumnuaypol","year":"2018","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2025073012483083000_7.1.e000349.39","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-1222"},{"key":"2025073012483083000_7.1.e000349.40","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2007.02429.x"},{"key":"2025073012483083000_7.1.e000349.41","doi-asserted-by":"crossref","first-page":"e186","DOI":"10.1111\/j.1468-3083.2012.04571.x","article-title":"Body weight increment in patients treated with infliximab for plaque psoriasis","volume":"27","author":"Florin","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025073012483083000_7.1.e000349.42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2012\/593039","article-title":"Weight gain and hair loss during anti-TNF therapy","volume":"2012","author":"Lutf","year":"2012","journal-title":"Int J Rheumatol"},{"key":"2025073012483083000_7.1.e000349.43","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23280"},{"key":"2025073012483083000_7.1.e000349.44","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2010.213"},{"key":"2025073012483083000_7.1.e000349.45","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-291X(88)81134-3"},{"key":"2025073012483083000_7.1.e000349.46","first-page":"G579","article-title":"Antibodies to tumor necrosis factor-alpha inhibit liver regeneration after partial hepatectomy","volume":"263","author":"Akerman","year":"1992","journal-title":"Am J Physiol"},{"key":"2025073012483083000_7.1.e000349.47","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0140165","article-title":"Differences in the prevalence of obesity, smoking and alcohol in the United States nationwide inpatient sample and the behavioral risk factor surveillance system","volume":"10","author":"Al Kazzi","year":"2015","journal-title":"PLoS One"},{"key":"2025073012483083000_7.1.e000349.48","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29367"}],"container-title":["BMJ Open Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjgast-2019-000349","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T19:48:43Z","timestamp":1753904923000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopengastro.bmj.com\/lookup\/doi\/10.1136\/bmjgast-2019-000349"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,4,15]]},"published-print":{"date-parts":[[2020,4]]}},"alternative-id":["10.1136\/bmjgast-2019-000349"],"URL":"https:\/\/doi.org\/10.1136\/bmjgast-2019-000349","relation":{},"ISSN":["2054-4774"],"issn-type":[{"value":"2054-4774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4]]}}}